RxDoctor Payments Data

Marlene Dietrich, MD

Neurology · Vancouver, WANPI 1124088406

Payments from drug & device makers

$453in general payments, 2019–2025

Across 12 payments — averaging $37.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$248
  • Biogen$28
  • EMD Serono, Inc.$25
  • Sanofi$24
  • Amneal Pharmaceuticals LLC$22
  • Novartis$22
  • plus $84 from 5 others

What the payments were for

  • Consulting fees$15033%
  • Food & beverage$30367%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$453 in reported general payments places this provider in the 50th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington

Medicare billing

Part B allowed, 2024
$64,328
Medicare patients
299
Services billed
1,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate12$238,263
WakixPitolisant Hcl14$220,417
Avonex (4 Pack)Interferon Beta-1a13$124,622
IngrezzaValbenazine Tosylate12$109,259
KeppraLevetiracetam18$46,135
Dimethyl Fumarate54$42,333
XcopriCenobamate26$31,662
SunosiSolriamfetol Hcl25$23,360
LamictalLamotrigine14$12,988
Aimovig AutoinjectorErenumab-Aooe17$12,482
NeuproRotigotine13$10,434
BelsomraSuvorexant19$8,937
Emgality PenGalcanezumab-Gnlm12$8,226
Lacosamide45$8,060
DepakoteDivalproex Sodium14$7,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$28$124,62213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 418 neurology providers in Washington.

Other neurology in Vancouver

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →